Evidence map›Paper›PMID 38486664›Full record

ArticleFrontline gastroenterology2024

Developing a generic business case for an advanced chronic liver disease support service.

Mark Wright, Sarah Willmore, Sumita Verma, Anita Omasta-Martin, Humraj Sahota, Wendy Prentice, Amelia Jane Stockley, Fiona Finlay, Julia Verne, Ben Hudson

Abstract read
In one paragraph

Article in Frontline gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mark WrightHepatology, University Hospital Southampton, Southampton, Hampshire, UK.ORCID 0000-0001-7046-241X
Sarah WillmoreHepatology, University Hospital Southampton, Southampton, Hampshire, UK.
Sumita VermaClinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, East Sussex, UK.ORCID 0000-0001-7021-8409
Anita Omasta-MartinPalliative Care, University Hospital Southamptom, Southampton, UK.
Humraj SahotaHepatology, University Hospital Southampton, Southampton, Hampshire, UK.
Wendy PrenticeDepartment of Palliative Care Medicine, King's College Hospital NHS Foundation Trust, London, London, UK.
Amelia Jane StockleySupportive and Palliative Care, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.
Fiona FinlayPalliative Care, Queen Elizabeth University Hospital Campus, Glasgow, UK.ORCID 0000-0001-8549-9231
Julia VernePublic Health, United Kingdom Department of Health and Social Care, London, UK.
Ben HudsonHepatology, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Liver disease deaths are rising, but specialist palliative care services for hepatology are limited. Expansion across the NHS is required. Methods: We surveyed clinicians, patients and carers to design an 'ideal' service. Using standard NHS tariffs, we calculated the cost of this service. In hospitals where specialist palliative care was available for liver disease, patient-level costs and bed utilisation in last year of life (LYOL) were compared between those seen by specialist palliative care before death and those not. Results: The 'ideal' service was described. Costs were calculated as whole time equivalent for a minimal service, which could be scaled up. From a hospital with an existing service, patients seen by specialist palliative care had associated costs of £14 728 in LYOL, compared with £18 558 for those dying without. Savings more than balanced the costs of introducing the service. Average bed days per patient in LYOL were reduced (19.4 vs 25.7) also intensive care unit bed days (1.1 vs 1.8). Despite this, time from first admission in LYOL to death was similar in both groups (6 months for the specialist palliative care group vs 5 for those not referred). Conclusions: We have produced a template business case for an 'ideal' advanced liver disease support service, which self-funds and saves many bed days. The model can be easily adapted for local use in other trusts. We describe the methodology for calculating patient-level costs and the required service size. We present a financially compelling argument to expand a service to meet a growing need.

Indexed as

cirrhosishealth economicsliver cirrhosis

Identifiers

PMID38486664
PMCPMC10935515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.